HRTX has 36-month beta value of 1.68. Analysts have mixed views on the stock, with 2 analysts rating it as a “buy,” 1 as “overweight,” 0 as “hold,” and 0 as “sell.”
The public float for HRTX is 151.01M, and currently, short sellers hold a 18.48% ratio of that float. The average trading volume of HRTX on December 10, 2024 was 3.09M shares.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
HRTX) stock’s latest price update
The stock of Heron Therapeutics Inc (NASDAQ: HRTX) has increased by 8.02 when compared to last closing price of 1.62.Despite this, the company has seen a gain of 43.44% in its stock price over the last five trading days. seekingalpha.com reported 2024-12-04 that Heron Therapeutics won a court case securing Cinvanti’s patents until 2035, and removing a significant legal overhang on its largest revenue contributor. The court win allows the company to focus on growing the business. Heron missed Q3 revenue estimates, but the company expects a recovery in Cinvanti sales in Q4 due to new account wins, and it shared encouraging trends of Zynrelef and Aponvie.
HRTX’s Market Performance
Heron Therapeutics Inc (HRTX) has experienced a 43.44% rise in stock performance for the past week, with a -1.13% drop in the past month, and a -3.85% drop in the past quarter. The volatility ratio for the week is 18.02%, and the volatility levels for the past 30 days are at 12.07% for HRTX. The simple moving average for the past 20 days is 34.15% for HRTX’s stock, with a -28.89% simple moving average for the past 200 days.
Analysts’ Opinion of HRTX
Many brokerage firms have already submitted their reports for HRTX stocks, with Rodman & Renshaw repeating the rating for HRTX by listing it as a “Buy.” The predicted price for HRTX in the upcoming period, according to Rodman & Renshaw is $7 based on the research report published on June 13, 2024 of the current year 2024.
CapitalOne, on the other hand, stated in their research note that they expect to see HRTX reach a price target of $6. The rating they have provided for HRTX stocks is “Overweight” according to the report published on April 23rd, 2024.
Needham gave a rating of “Buy” to HRTX, setting the target price at $5 in the report published on March 13th of the current year.
HRTX Trading at 7.11% from the 50-Day Moving Average
After a stumble in the market that brought HRTX to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -55.47% of loss for the given period.
Volatility was left at 12.07%, however, over the last 30 days, the volatility rate increased by 18.02%. Over the last 50 days, in opposition, the stock is trading -12.06% lower at present.
During the last 5 trading sessions, HRTX rose by +43.44%, which changed the moving average for the period of 200-days by -32.69% in comparison to the 20-day moving average, which settled at $1.3045. In addition, Heron Therapeutics Inc saw 2.94% in overturn over a single year, with a tendency to cut further gains.
Stock Fundamentals for HRTX
Current profitability levels for the company are sitting at:
- -0.18 for the present operating margin
- 0.68 for the gross margin
The net margin for Heron Therapeutics Inc stands at -0.19. The total capital return value is set at -0.19.
Based on Heron Therapeutics Inc (HRTX), the company’s capital structure generated 1.3 points at debt to capital in total, while cash flow to debt ratio is standing at -0.05. The debt to equity ratio resting at -4.36. The interest coverage ratio of the stock is -11.96.
Currently, EBITDA for the company is -103.79 million with net debt to EBITDA at -6.87. When we switch over and look at the enterprise to sales, we see a ratio of 2.84. The receivables turnover for the company is 2.2for trailing twelve months and the total asset turnover is 0.67. The liquidity ratio also appears to be rather interesting for investors as it stands at 2.28.
Conclusion
To put it simply, Heron Therapeutics Inc (HRTX) has had a mixed performance in recent times. Analysts have a bullish opinion on the stock, with some rating it as a “buy” and others as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
